KalVista Pharmaceuticals (NASDAQ: KALV) reported Q3 EPS of ($0.94), $0.10 better than the analyst estimate of ($1.04).

Cash Position: Cash, cash equivalents and marketable securities were $142.1 million as of July 31, 2022, compared to $166.2 million as of April 30, 2022. The decrease in the net cash and marketable securities position was due to cash consumption from operating expenses.

For earnings history and earnings-related data on KalVista Pharmaceuticals (KALV) click here.